Trials / Completed
CompletedNCT00915460
Open-Label Safety Extension Study of Avonex
An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 408 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1a (Avonex) | dosage and frequency as per Biogen Idec protocol |
Timeline
- Start date
- 1999-09-01
- Primary completion
- 2003-06-01
- Completion
- 2003-07-01
- First posted
- 2009-06-08
- Last updated
- 2009-06-08
Source: ClinicalTrials.gov record NCT00915460. Inclusion in this directory is not an endorsement.